



Second World Conference on Nanomedicine and Drug Delivery

11-13 March 2011, Kottayam, India

BIOMEDICAL AND RELATED APPLICATIONS OF SECOND GENERATION POLYAMIDOAMINES

Fabio Fenili^a, Amedea Manfredi^a, Roberta Cavalli^b, Simon C.W. Richardson^c, Elisabetta Ranucci^a, Paolo Ferruti^a.

fabio.fenili@unimi.it

^aDipartimento di Chimica Organica e Industriale, Università degli Studi di Milano, via Venezian 21, 20133 Milano, Italy;

^bDipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via P. Giuria 6, 10125 Torino, Italy;

^cSchool of Science, University of Greenwich at Medway, Central Avenue, Chatham Maritime, Kent ME4 4TB, UK.

BIOMEDICAL AND RELATED APPLICATIONS OF SECOND GENERATION POLYAMIDOAMINES

CONTENT:

1. Synthesis and properties of PAAs
2. PAAs as cytoplasmic delivery vehicles of immunotoxines
3. PAA-cholesterol nanoparticles
4. PAA- β -Cyclodextrin nanoparticles
5. Conclusions



BIOMEDICAL AND RELATED APPLICATIONS OF SECOND GENERATION POLYAMIDOAMINES

- 1. Synthesis and properties of PAAs**
2. PAAs as cytoplasmic delivery vehicles of immunotoxines
3. PAA-cholesterol nanoparticles
4. PAA- β -Cyclodextrin nanoparticles
5. Conclusions



PROPERTIES OF PAAs

- ✓ PAAs are usually **water soluble**;
- ✓ PAAs are **polymeric bases of low to medium strength**;
- ✓ PAAs are **biocompatible, biodegradable and non-toxic**;
- ✓ **Easily functionalized** with several different functional groups;
- ✓ **Amphoteric PAAs show stealth properties and EPR effect.**

Franchini, J.; Ferruti, F. *Chapter 16 in Polymeric gene delivery: Principles and Applications.*, Mansoor M. Amiji, CRC Press, 2005.

Ferruti, P.; Marchisio, M.A.; Duncan, R *Macromol. Rapid Commun.* **2002**, *23*, 332.



PAA name and structure


pK_a

I.P.

Percentage of Charged Units

pH=5.5

pH=7.4




pK_{a1}=2.1
pK_{a2}=3.25
pK_{a3}=7.5

5.5

40%
(-)

2%
(-)




pK_{a1}=8.1
pK_{a2}=6.9
pK_{a3}=3.8
pK_{a4}=2.8

>10


95%
(+)

55%
(+)

ISA23



ISA1



Ferruti, P.; Manzoni, S.; Richardson, S.C.W.; Duncan, R.; Patrick, N.G.; Mendichi, R.; Casolaro, M. *Macromolecules* **2000**, *33*, 7793-7800.

Franchini, J.; Ranucci, E.; Ferruti, P.; Rossi, M.; Cavalli, R. *Biomacromolecules* **2006**, *7* (4), 1215-1222.

Ranucci, E.; Ferruti, P.; Lattanzio, E.; Manfredi, M.; Rossi, M.; Mussini, P.R.; Chiellini, F.; Bartoli, C. *Journal of Polymer Science: Part A: Polymer Chemistry* **2009**, *4*, 6977.



TOXICITY OF PAAs

Sample	\overline{Mn}	IC ₅₀ (mg/mL) on B16F10 cells
ISA23	21500	> 5.00
ISA1	9500	3.05 ± 0.70
POLY-L-LYSINE	56500	0.05 ± 0.01
DEXTRAN	70000	> 5.00

Cytotoxicity test on B16F10 cell line.

Sample	\overline{Mn}	IC ₅₀ (mg/mL) on Balb/3T3 Clone A31
ISA23	20300	> 5.00
ISA1	14500	2.17 ± 0.75
POLY-L-LYSINE	56500	0.05 ± 0.01
DEXTRAN	70000	> 5.00

Cytotoxicity test on mouse embryo fibroblasts Balb/3T3 Clone A31 cell line.




Ferruti, P.; Manzoni, S.; Richardson, S.C.W.; Duncan, R.; Patrick, N.G.; Mendichi, R.; Casolaro, M. *Macromolecules* **2000**, *33*, 7793-7800.



Franchini, J.; Ranucci, E.; Ferruti, P.; Rossi, M.; Cavalli, R. *Biomacromolecules* **2006**, *7* (4), 1215-1222.

INTRACELLULAR TRAFFICKING PAAs

Secretory pathway Endocytic pathway



Co-localization of ISA1 with EEA1



Co-localization of ISA1 and ISA23 with lysotracker



BIOMEDICAL AND RELATED APPLICATIONS OF SECOND GENERATION POLYAMIDOAMINES

1. Synthesis and properties of PAAs
- 2. PAAs as cytoplasmic delivery vehicles of immunotoxines**
3. PAA-cholesterol nanoparticles
4. PAA- β -Cyclodextrin nanoparticles
5. Conclusions



PAAAs AS CYTOPLASMIC DELIVERY VEHICLES OF IMMUNOTOXINES

The development and successful application of therapeutic proteins is often hindered by several difficulties, as for instance insufficient stability and shelf-life, costly production, immunogenic and allergic potential, as well as poor bioavailability and sensitivity towards proteases.

To overcome these problems, a possible approach is to **modify proteins by covalently conjugating them with water-soluble polymers**, thus increasing their plasma residence, reducing protein immunogenicity and increasing their therapeutic index.




Duncan, R. *Nat. Rev. Drug Discov.* **2003**, 2, 214-221.

Duncan, R. *Nature Review* **2006**, 6, 688-701.

Increasing attention has devoted to the nature of the chemical linkage between the polymer backbone and protein.

In this work, two PAAs bearing 2-ethenyldithiopyridine pendants were used to investigate their ability to mediate intracellular delivery of the ribosome-inactivating gelonin.

PAA-SSPy



GELONIN



Ribosome-inactivating protein.


It doesn't contain the cell-binding subunit that promotes its internalization by endocytosis.

Emilitri, E.; Ranucci, E.; Ferruti, P. *J. Polym. Sci., Part A: Polym. Chem.* **2005**, *43*, 1404.

Ranucci, E.; Ferruti, P.; Suardi, M.A.; Manfredi, A. *Macromol. Rapid Commun.* **2007**, *28*, 1243-1250.




PAAS AS CYTOPLASMIC DELIVERY VEHICLES OF IMMUNOTOXINES




PAAs AS CYTOPLASMIC DELIVERY VEHICLES OF IMMUNOTOXINES

ISA23-SSPy



ISA1-SSPy




GPC-LS

NMR Spectroscopy

Sample	\overline{M}_n	\overline{M}_w	PD	% of functions
ISA1	18000	30000	1.93	8.67
ISA23	12700	23600	1.86	9.2


ISA1-SSPy

Pyridine ring



PAA-SSPY CYTOTOXICITY

ISA1-SSPy and ISA23-SSPy were tested by direct contact assay for 72 hours using B16F10 and Vero cells.



Sample	IC ₅₀ (mg/mL) on B16F10 cells	IC ₅₀ (mg/mL) on VERO cells
ISA1-SSPy	2.5	1.5
ISA23-SSPy	> 5.00	5.00
PEI	0.04 ± 0.01	0.05 ± 0.01
DEXTRAN	> 5.00	> 5.00



SUB-CLONING OF GELONIN

PAA-SSPy polymers were used to prepare PAA-gelolin complexes in which the polymeric chain was linked to the bioactive moieties by a disulfide bridge.

To achieve this aim, two types of gelolin were sub-cloned:

6H-V5-Gelolin



Gelolin-HA-Cys-6H




Plasmids encoding both the two protein were made by sub-cloning an open reading frame coding for gelolin into a commercially available bacterial expression cassette (pET151/D Topo).

Protein were expressed using BL21(DE3) Competent E. Coli.





PAAs AS CYTOPLASMIC DELIVERY VEHICLES OF IMMUNOTOXINES

6H-V5-Gelolin



Gelolin-HA-Cys-6H



1:1000 6XHis Monoclonal Antibody

1:500 Anti-mouse Ig, horseradish whole antibody

Gelolin-HA-Cys-6H

MKGNMVKVYWIKIAVATWFCCTIVL
 GSTARIFSLPTNDEEETSRTLGLDTVS
 FSTKGATYITYVNFLNELRVKLP
 NSHGIPLLRKKCDDPGKCFVLVALSN
 DNGQLAEIAIDVTSVYVVGQVRNR
 SYFFKDAPDAAYEGLFKNTIKTRLHF
 GGSYPSLEGEKAYRETTDLGIEPLRIGI
 KKL DENAIDNYKPT EIASLLVVIQM
 VSEARFTFIENQIRNNFQQRIRPAN
 NTISLENKWGKLSFQIRTSGANGMF
 SEAVELERANGKYYVTAVDQVKPKI
 ALLKFVDKDPKTSLAAELIIQNYESLV
 GFDES LVGFDYPYDVPDYARCAHHH
 HHH.


6H-V5-Gelolin

MHHHHHHGKPIP NLLGLDSTENLYF
 QGIDPFTMKGNMVKVYWIKIAVATWFC
 CTTIVL GSTARIFSLPTNDEEETSRTLGL
 DTVSFSTKGATYITYVNFLNELRVKLP
 GNSHGIPLLRKKCDDPGKCFVLVALSN
 DNGQLAEIAIDVTSVYVVGQVRNRSY
 FFKDAPDAAYEGLFKNTIKTRLHF
 PSLEGEKAYRETTDLGIEPLRIGIKKLD
 NAIDNYKPT EIASLLVVIQM VSEARF
 TFIENQIRNNFQQRIRPANNTISLENK
 WGKLSFQIRTSGANGMFSEAVELERA
 NGKYYVTAVDQVKPKIALLKFVDKDP
 KTSLAAELIIQNYESLVGFD




GELONIN TOXICITY

Gelolin-HA-Cys-6H



6H-V5-Gelolin



In all further experiments, non toxic concentrations of 6H-V5 Gelolin and Gelolin HA-Cys-6H were used.



1.4 µg/mL


14 µg/mL

1.4 µg/mL



ISA23-SS-GELONIN CONJUGATES: TOXICITY


Cytotoxicity experiments were performed using fixed concentration of protein and polymer concentrations up to 2 mg/mL on B16F10 cells.



ISA23-SSPy was unable to mediate toxin delivery in the B16F10 cells.

ISA1-SS-GELONIN CONJUGATES: TOXICITY

ISA1-SSPy efficiently promoted the intracytoplasmic delivery of gelonin.



ISA1-SSPy-6H-V5 Gelonin → IC₅₀ : 100 µg/mL

ISA1-SSPy-Gelonin HA-Cys-V5 → IC₅₀ : 100 µg/mL

ISA1-SSPy-Gelonin HA-Cys-6H (14 µg/mL) IC₅₀ : 10 µg/mL



S.C.W. Richardson et al. *Journal of Controlled Release* **2001**, *77*, 225–232



Journal of Controlled Release 77 (2001) 225–232

journal of
controlled
release

www.elsevier.com/locate/jconrel

Poly(amidoamine)-mediated intracytoplasmic delivery of ricin A-chain and gelonin

N.G. Patrick^a, S.C.W. Richardson^a, M. Casolaro^b, P. Ferruti^c, R. Duncan^{a,*}

^aCentre for Polymer Therapeutics, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3XF, UK

^bDipartimento di Scienze e Tecnologie Chimiche e dei Processi, Università di Siena, P.le dei Matellini 46, 53100 Siena, Italy

^cDipartimento di Chimica Organica e Industriale, Università degli Studi di Milano, Via Venezian 21, 20133, Milano, Italy

Received 15 May 2001; accepted 7 September 2001

Abstract

Poly(amidoamine)s (PAAs) are water-soluble synthetic polymers designed to be biodegradable and biocompatible. Moreover, they display membrane disruptive properties in response to a decrease in pH. This attribute confers PAAs with endocytic escape properties *in vitro* and *in vivo*. A model system was developed to quantify their ability to promote the endocytic escape of macromolecules that may be interesting as therapeutic agents. Here, two PAAs (ISA 1 and 4) were incubated with B16F10 cells *in vitro* together with two non-permeant toxins: either ricin A-chain (RTA) or gelonin. The relatively non-toxic PAAs ISA 1 and 4 ($IC_{50} > 1.5$ mg/ml) restored activity to the inherently inert toxins. The IC_{50} values for the ISA 1/RTA and ISA 1/gelonin combinations were 0.65 ± 0.05 and 0.55 ± 0.12 mg/ml, respectively. Similarly, when ISA 4 was incubated with a non-toxic combination of RTA and gelonin the IC_{50} value decreased to 0.57 ± 0.03 and 0.43 ± 0.26 mg/ml, respectively. In contrast, the neutral polymer dextran and the PAA ISA 22 were unable to mediate this effect. These observations suggest that specific PAA–toxin combinations warrant further development as novel therapeutics. © 2001 Elsevier Science B.V. All rights reserved.

Keywords: Ricin; Gelonin; Poly(amidoamine)s; Non-viral vector; Cytotoxic delivery

1. Introduction

Poly(amidoamine)s (PAAs) have been developed as biomedical materials and water soluble drug-carriers, as reviewed in Refs. [1–3]. This family of polymers is currently being developed as a synthetic alternative to fusogenic peptides as they display pH-dependent conformational changes upon protonation at reduced pH which leads to membrane per-

turbation [4–6]. This property has been shown to confer PAAs with the capacity to promote transfection of pSV- β -galactosidase [6]. Furthermore, PAAs can be designed to be biodegradable, biocompatible and non-hepatotoxic [5,7] suggesting their potential for a wide range of *in vivo* applications.

Plant and bacterial toxins have been widely explored as anticancer agents, particularly in the form of immunotoxins (reviewed in Ref. [8]). Therefore, here we chose to investigate the ability of PAAs to mediate intracellular delivery of two ribosome-inactivating toxins, ricin and gelonin. Ricin, derived from *Ricinus communis* beans [9], is a highly cytotoxic

*Corresponding author. Tel.: +44-1920-874-180; fax: +44-1920-874-536.

E-mail address: duncan@cf.ac.uk (R. Duncan).

ISA1-SSPy promoted the intracytoplasmic delivery of gelonin more efficiently than the parent ISA1

ISA1-Gelonin



IC_{50} : 522 μ g/mL.




ISA1-SSPy-HA-Cys-6H and ISA1-SSPy-6H-V5 Gelonin showed same results (IC_{50} :100 μ g/mL).

ISA1-SSPy is able to interact with disulfide groups and hydrophobic domains of the protein, giving stable complexes.

Ricin structure. The **A** chain (RIP) is shown in blue and the **B** chain (cell binding sub-unit) in orange.

ISA1-SSPy acts as synthetic mimicking of the cell binding sub-unit of the Ricin toxin that mediates the internalization of gelonin into the cytosol.



BIOMEDICAL AND RELATED APPLICATIONS OF SECOND GENERATION POLYAMIDOAMINES

1. Synthesis and properties of PAAs
2. PAAs as cytoplasmic delivery vehicles of immunotoxines
- 3. PAA-cholesterol nanoparticles**
4. PAA- β -Cyclodextrin nanoparticles
5. Conclusions



PAA-CHOLESTEROL NANOPARTICLES

Improvement in drug controlled release is one of the main challenges of modern pharmacology in order to reduce side effects of therapies and to exploit drug potential:


- ✓ “Solubilization” of lipophilic drugs;
- ✓ Specific targeting and release of drugs;
- ✓ Sustained release of soluble/insoluble drugs;
- ✓ Protection of proteins or genes in transfection.

The use of polymers in designing new drugs architectures, most often in the form of nanoparticles (NP) is one of the most promising possibilities to achieve these goals.



PAA-CHOLESTEROL NANOPARTICLES

Using the PAA-SSPy precursors already shown, a family of amphoteric polymers containing cholesterol pendants linked through disulfide bonds was synthesized.




ISA23 backbone

Stealth properties

IC₅₀ = 5 mg/ml (B16 cells)

Cholesterol pendants



Cholesterol is an essential structural component of mammalian cell membranes, where it is required to establish proper membrane permeability and fluidity.





PAA-cholesterol conjugates are able to spontaneously self assemble in nanoparticles.

PAA-SS-CHOLESTEROL CONJUGATES: SYNTHESIS





ISA1-SSPy




ISA23-SSPy



PAA-SS-CHOLESTEROL CONJUGATES: SYNTHESIS




PAA-CHOLESTEROL NANOPARTICLES



SPONTANEOUSLY ASSEMBLED PAA-CHOLESTEROL NP

TEM MICROGRAPH AND DLS



Sample	% Cholesterol	D (nm)	PI
ISA1-SSChol1	8	243 ± 16	0.20
ISA1-SSChol2	15	264 ± 21	0.18
ISA23-SSChol1	8	124 ± 6	0.11
ISA23-SSChol2	15	131 ± 7	0.13

D = average diameter.
PI = polydispersity index.

CYTOTOXICITY


Sample	IC ₅₀ (mg/mL) on 3T3/BALB-c cells
ISA1-SSChol	> 2
ISA23-SSChol	> 3

The cytotoxicity of PAA-cholesterol conjugates was assessed by in vitro cytotoxicity assays performed against 3T3/BALB-c Clone A31 cell lines




^1H NMR OF PAA-CHOLESTEROL CONJUGATES

NMR spectrum in D_2O



NMR spectrum in CDCl_3




Ranucci, E.; Suardi, M. A.; Annunziata, R.; Ferruti, P.; Chiellini, F.; Bartoli, C. *Biomacromolecules*, **2008**, 9 (10), 2693-2704




FORMULATION OF DRUG LOADED PAA-CHOLESTEROL NP

ELECTROSPRAY




Electrospray is a method of liquid atomization that consists in the dispersion of a solution into small charged droplets by an electric field.

Doxorubicin loaded (9%) PAA-cholesterol nanoparticles




Tamoxifen loaded (5%) PAA-cholesterol nanoparticles



FORMULATION OF DRUG LOADED PAA-CHOLESTEROL NP

ELECTROSPRAY



Cellular uptake of doxorubicin-loaded and fluorescent PAA-cholesterol nanoparticles with confocal laser scanning microscopy.

After 1 hour the nanoparticles were internalized in the cells.



FORMULATION OF DRUG LOADEAD PAA-CHOLESTEROL NP

SOLVENT INJECTION METHOD

PAA-cholesterol nanoparticles were formulated by the solvent injection method from water-ethanol mixtures.

The nanoparticles showed no hemolytic activity tested on in vitro red blood cell.

Sample	D (nm)	PI	PZ (mV)
ISA23-SSChol	60 ± 10	0.26	-14.86 ± 0.99

D = average diameter.
PI = polydispersity index.
PZ = zeta potential



BIOMEDICAL AND RELATED APPLICATIONS OF SECOND GENERATION POLYAMIDOAMINES

1. Synthesis and properties of PAAs
2. PAAs as cytoplasmic delivery vehicles of immunotoxines
3. PAA-cholesterol nanoparticles
- 4. PAA- β -Cyclodextrin nanoparticles**
5. Conclusions



PAA- β -CYCLODEXTRIN NANOPARTICLES

Unsubstituted β -cyclodextrin (β -CD) is poorly soluble in water and often gives nearly insoluble complexes with hydrophobic molecules.




Characteristics	β -CD
Units	7
PM	1135
Water solubility	1.85 (g/100 mL)
Cavity volume	262 Å
$[\alpha]_D^{25^\circ\text{C}}$	162.5 + 0.5
pK_a	12.2

Many chemical modifications have been proposed for increasing the solubility of β -CD and its complexes in aqueous media but only relatively few examples of β -CD conjugates with biocompatible hydrophilic synthetic polymers can be found in literature.



PAA- β -CYCLODEXTRIN NANOPARTICLES

β -CD-PAA copolymers can be obtained as hyperbranched soluble products, or as crosslinked nanoparticulated products.



In water at 20-25°C and $\text{pH} \geq 11$, approximately 5 hydroxyl groups per β -CD molecule undergo Michael-type addition to bis-acrylamides.

This means that β -CD acts as **multifunctional** monomer in stepwise polyadditions to bisacrylamides.



SYNTHETIC STRATEGIES

FLORY-STOCKMAYER EQUATION

Kinetic control

$$p_c = \frac{1}{\{r[1 + \rho(f - 2)]\}^{1/2}}$$

Stoichiometric control

$$r_c = \frac{1}{1 + \rho (f - 2)}$$

r = ratio between the number of functions of the multifunctional monomer and the total number of the same functions

f = number of functions of the multifunctional monomer

r = starting ratio among the complementary functions (“a” and “b”)

p_c = reaction conversion degree at which gelling takes place;


r_c = critical functiona ratio. Below this value cross-linking cannot take place.



PAA- β -CD NANOPARTICLES

HIGH PRESSURE HOMOGENIZATION (HPH)


High pressure homogenizer



PAA micro- and nanogels are obtained by high pressure homogeneization of hydrogel suspensions.

Procedure:



- 1) mechanical grinding at 12000 rpm
- 2) Homogeneization cycles at 2000 – 5000 KPa



Particles rupture in precision gap during HPH process




TOXICITY





Preliminary biological evaluations carried out for hyperbranched PAA- β -CD including In-vitro MCF-7 cell viability tests and In-vivo haemolytic activity (human RBC), have confirmed the biocompatibility of the polymer.

PAA- β -CD/PACLITAXEL NP



PACLITAXEL



PAA- β -CD can be loaded with Paclitaxel up to 5% of their own weight forming nanoparticles with diameter < 500 nm

PAA- β -CD/PACLITAXEL NP




Native “solution”


The same “solution” after
lyophilisation an
redissolution in water.



PAA- β -CD/PACLITAXEL NP: TOXICITY



■ Paclitaxel ■ β CD/PAA/Paclitaxel




■ Paclitaxel ■ β CD/PAA/Paclitaxel




Paclitaxel even complexed by the polymeric system, maintains its efficiency in the inhibition of cancer cell growth (In vitro MCF-7 cell cultures).





PAA- β -CD NANOPARTICLES



DEXAMETHASONE



PROGESTERONE



BIOMEDICAL AND RELATED APPLICATIONS OF SECOND GENERATION POLYAMIDOAMINES

1. Synthesis and properties of PAAs
2. PAAs as cytoplasmic delivery vehicles of immunotoxines
3. PAA-cholesterol nanoparticles
4. PAA- β -Cyclodextrin nanoparticles
- 5. Conclusions**



CONCLUSIONS

PAAAs constitute a very versatile family of ionic polymers that are easily synthesized and can be designed to be biocompatible and degradable in the body fluids.

They warrant potential, inter alia, as intracytoplasmic delivery vehicles of protein, as nanoparticles for the release of lipophilic drugs and many other applications in the nanomedicine field.

As a final observation, the unique combination of biotechnologically relevant properties of PAAAs are still waiting to be fully exploited.



AKNOWLEDGMENTS

Milan University lab. group

Prof. Elisabetta Ranucci

Prof. Paolo Ferruti

Dr Amedea Manfredi

Greenwich University lab. group:

Prof. Simon Richardson

Arun Kumar Kotta

Paul Dyer

Marie Petit

Tathiana Christides

Turin University lab. group:

Prof. Roberta Cavalli

Agnese Bisazza



THANK YOU

FOR YOUR

KIND ATTENTION

